Malignant Melanoma (First-Line Unresectable/Metastatic) | Decision Base | US | 2015
Will the Emerging Immunotherapies and BRAF/MEK Inhibitor Combinations Meet Physicians’ and Payers’ Expectations?
In recent years, several new, high-priced therapies have been approved for use in first-line unresectable/metastatic malignant melanoma, making this relatively small market more dynamic and competitive. The launch of these agents has significantly altered the treatment algorithm and improved the outlook for patients; nevertheless, our research indicates that significant clinical and commercial opportunity remains for therapies that can further prolong overall survival (OS). Several therapies are in late-stage development for first-line unresectable/metastatic malignant melanoma, all of which are showing considerable potential for improving efficacy outcomes in this indication.
